Literature DB >> 21509306

Challenges of childhood uveitis.

Reem Abdwani1.   

Abstract

Chronic uveitis is a rare, but potentially sight-threatening disease. The most common cause of chronic non-infectious uveitis is "idiopathic uveitis". However, some systemic diseases are associated with chronic uveitis in children and are discussed. Chronic uveitis merits special consideration in children. The unique differences in children are highlighted with special consideration for the diagnostic and therapeutic challenges encountered in their management. While corticosteroids remain the mainstay of initial therapy, a wide range of immunosuppressive agents have been used with variable success. The role of immonomodulatory agents such as methotrexate, cyclosproin and some of the new biologic agents such as etanecept, infliximab, adalimumab are reviewed. Successful outcomes may be achieved with appropriate immunosuppressant therapy when given early in the disease, although clinical trials are required to define the true efficacy of this strategy.

Entities:  

Keywords:  Treatment; Uveitis

Year:  2009        PMID: 21509306      PMCID: PMC3074809     

Source DB:  PubMed          Journal:  Sultan Qaboos Univ Med J        ISSN: 2075-051X


  50 in total

1.  Population based assessment of uveitis in an urban population in southern India.

Authors:  L Dandona; R Dandona; R K John; C A McCarty; G N Rao
Journal:  Br J Ophthalmol       Date:  2000-07       Impact factor: 4.638

2.  Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997.

Authors:  R E Petty; T R Southwood; J Baum; E Bhettay; D N Glass; P Manners; J Maldonado-Cocco; M Suarez-Almazor; J Orozco-Alcala; A M Prieur
Journal:  J Rheumatol       Date:  1998-10       Impact factor: 4.666

3.  Adalimumab therapy for childhood uveitis.

Authors:  Liza B Vazquez-Cobian; Thomas Flynn; Thomas J A Lehman
Journal:  J Pediatr       Date:  2006-10       Impact factor: 4.406

4.  International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease.

Authors:  E Bloch-Michel; R B Nussenblatt
Journal:  Am J Ophthalmol       Date:  1987-02-15       Impact factor: 5.258

5.  Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis.

Authors:  M Santos Lacomba; C Marcos Martín; J M Gallardo Galera; M A Gómez Vidal; E Collantes Estévez; R Ramírez Chamond; M Omar
Journal:  Ophthalmic Res       Date:  2001 Sep-Oct       Impact factor: 2.892

6.  Vogt-Koyanagi-Harada syndrome in children compared to adults.

Authors:  K F Tabbara; P S Chavis; W R Freeman
Journal:  Acta Ophthalmol Scand       Date:  1998-12

7.  Switching biologic agents for uveitis.

Authors:  N Dhingra; J Morgan; A D Dick
Journal:  Eye (Lond)       Date:  2009-07-31       Impact factor: 3.775

8.  Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis.

Authors:  R K Saurenmann; A V Levin; J B Rose; S Parker; T Rabinovitch; P N Tyrrell; B M Feldman; R M Laxer; R Schneider; E D Silverman
Journal:  Rheumatology (Oxford)       Date:  2006-02-03       Impact factor: 7.580

9.  Uveitis in children.

Authors:  P Pivetti-Pezzi
Journal:  Eur J Ophthalmol       Date:  1996 Jul-Sep       Impact factor: 1.922

10.  Orbital and childhood sarcoidosis.

Authors:  J A Khan; D L Hoover; J Giangiacomo; B H Singsen
Journal:  J Pediatr Ophthalmol Strabismus       Date:  1986 Jul-Aug       Impact factor: 1.402

View more
  2 in total

1.  Pediatric Noninfectious Uveitis in a Tertiary Referral Center in Jordan: Clinical Spectrum and Immunomodulatory Treatment.

Authors:  Raed Alzyoud; Motasem Alsuwaiti; Hiba Maittah; Boshra Aladaileh; Mohammed Nobani; Ayman Farhan; Hadeel Alqurieny; Ahmed Khatatbeh; Zeyad Habahbeh
Journal:  Cureus       Date:  2022-06-11

2.  AAV-mediated expression of HLA-G1/5 reduces severity of experimental autoimmune uveitis.

Authors:  Elizabeth Crabtree; Liujiang Song; Telmo Llanga; Jacquelyn J Bower; Megan Cullen; Jacklyn H Salmon; Matthew L Hirsch; Brian C Gilger
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.